FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	OMB APPROVAL									
	OMB Number:	3235-0287								
	Estimated average burden									
-	hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Vaddi Krishna</u>						2. Issuer Name and Ticker or Trading Symbol Prelude Therapeutics Inc [PRLD]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O PRELUDE THERAPEUTICS INCORPORATED 200 POWDER MILL ROAD						3. Date of Earliest Transaction (Month/Day/Year) 09/29/2020								X Officer (give title Other (specify below) President, CEO					
(Street)	GTON I	DE	19801		4. If Amendment, Date of				of Original Filed (Month/Day/Year)					Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State)	(Zip)	n Davis				idiaa Aa		Die		-	noficial.	h . O					
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Transa Date (Month/L					action 2A. De Execu- ay/Year) if any			3. 4. Sec Transaction Dispos Code (Instr. 5)		4. Securiti	rities Acquired (A) or ed Of (D) (Instr. 3, 4 and		5. Amount of Securities Beneficially Owned Following		6. Owne Form: D (D) or In (I) (Instr	Direct In	Nature of direct eneficial wnership		
						,		Code	v	Amount	(A) or (D)	Price	Reported Transactio (Instr. 3 an	on(s)			ıstr. 4)		
Common Stock													1,045,5	1,045,519(1)					
Common Stock			09/29	29/2020				С		101,47	77 A	(2)	101,4	177	I		ee ootnote ⁽³⁾		
Common Stock 09/29				09/29	/202	/2020		С		32,876		(2)	551,776		I B		y Trust ⁽⁴⁾		
Common Stock 09/29/				/202	2020		С		32,876	6 A	(2)	551,7	774	1 I		y Trust ⁽⁵⁾			
Common Stock													423,6	555	I	В	y Trust ⁽⁶⁾		
			Table II -								osed of			Owned					
Derivative Security (Instr. 3)	Title of 2. 3. Transaction 3A. Deemed Execution Date Execution Date, if any			i 4. Date, Ti	ransaction ode (Instr. Secondary or D of (I		5. Number of 6 Derivative E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)		
				С	ode	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	ion(s)			
Series A Preferred Stock	(2)	09/29/2020			С			101,477	(2)		(2)	Common Stock	101,477	\$0.00	0		I	See Footnote ⁽³⁾	
Series A Preferred Stock	(2)	09/29/2020			С			32,876	(2)		(2)	Common Stock	32,876	\$0.00	0		I	By Trust ⁽⁴⁾	
Series A Preferred Stock	(2)	09/29/2020			С			32,876	(2)		(2)	Common Stock	32,876	\$0.00	0		I	By Trust ⁽⁵⁾	

Explanation of Responses:

- 1. Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.
- 2. The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date.
- 3. The Reporting Person is the manager of Sidus Ventures LLC. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
- 4. The Reporting Person is the investment advisor of the Blue Sky Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
- 5. The Reporting Person is the investment advisor of the Brocade Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
- 6. The Reporting Person is a beneficiary of the Dolphin City Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

Remarks:

<u>/s/ Brian Piper, as Attorney-in-</u> Fact for Krishna Vaddi

09/29/2020

** Signature of Reporting Person

Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.